Opus Genetics

IRD (NasdaqCM)

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in inherited retinal diseases and other ophthalmic disorders. Its lead programs include OPGx-LCA5 (Phase 1/2 for LCA5-associated IRD) and OPGx-BEST1 for BEST1-associated retinal disease. It also has multiple preclinical retinal gene therapies, plus Phentolamine Ophthalmic Solution and APX3330 for diabetic retinopathy. Founded in 2018 in Durham, North Carolina; formerly Ocuphire Pharma (renamed Nov 2020).